When small biotechnology companies need money to keep their work going, they often turn to selling shares. One recent example involves a firm working on treatments for brain diseases that slowly destroy nerve cells. Clene Inc. (NASDAQ: CLNN) priced an offering of 1,000,000 shares at $7.00 each, bringing in $7 million before fees. This move, handled by Canaccord Genuity as the main underwriter, aims to support the company’s main project, a drug called CNM-Au8.
Clene focuses on neurodegenerative conditions like amyotrophic lateral sclerosis, or ALS, and multiple sclerosis. These diseases damage neurons and the protective coverings around nerves, leading to loss of movement, speech, and other functions over time. The company’s approach uses tiny particles made from pure gold, known as clean-surfaced nanocrystals. These particles slip into brain cells to improve energy production, helping neurons resist damage and keep working.
CNM-Au8 has shown promise in clinical trials for ALS patients. In the RESCUE-ALS Phase 2 study, those on the 30 mg daily dose had a 60% lower risk of death over 12 months compared to placebo. The HEALEY ALS Platform Trial added weight, with treatment groups seeing roughly a 10% drop in neurofilament light chain, or NfL, a key blood marker for nerve injury. Patients who switched from placebo to CNM-Au8 matched the steady NfL levels of early starters, and survival trends improved alongside lower glial fibrillary acidic protein, signaling less brain inflammation. Clene plans an FDA Type C meeting soon and targets a New Drug Application by mid-2026 via accelerated approval.
Micro-cap biotechs like Clene face tough funding hurdles. Clene reported $5.2 million cash at 2025 year-end. A January 2026 raise added over $28 million in milestone-based tranches, funding operations to Q3 2026 or early 2027. This $7 million infusion, netting $6.4 million after fees, covers NDA work, expanded access programs, Phase 3 planning, manufacturing scale-up, and seed projects. A 60-day insider lock-up curbs quick sales for stability.
Financing brings dilution, where new shares shrink existing stakes, a common overhang in this space. Still, tying funds to milestones like regulatory filings shows discipline. Clene priced above recent trading levels, unlike some peers facing steeper discounts. Firms like Annovis Bio Inc. (NYSE: ANVS), another micro-cap chasing Alzheimer’s and Parkinson’s fixes, navigate similar cash crunches with repeated raises. Revenue for Clene hovers under $200,000 annually, standard for trial-focused players with high burn rates. Safety stands out, backed by over 1,000 patient-years without serious drug issues.
For small biotechs like Clene, every funding round tests investor patience against scientific promise. This latest capital extends the runway just enough to reach key FDA milestones that could validate years of work.
